Cargando…
Association between baseline C‑reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta‑analysis
The prognostic impact of baseline C-reactive protein (CRP) in patients with cancer receiving immune checkpoint inhibitors (ICIs) is unclear. The present meta-analysis aimed to review the prognostic value of baseline C-reactive protein (CRP) levels for patients with cancer receiving immunotherapy. El...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318603/ https://www.ncbi.nlm.nih.gov/pubmed/37408861 http://dx.doi.org/10.3892/etm.2023.12060 |
_version_ | 1785068071003619328 |
---|---|
author | Xu, Yu Ma, Ke Zhang, Fan Ma, Minting Hong, Lei Wang, Jing Li, Suping Sun, Panpan Wang, Junyan Wei, Suju |
author_facet | Xu, Yu Ma, Ke Zhang, Fan Ma, Minting Hong, Lei Wang, Jing Li, Suping Sun, Panpan Wang, Junyan Wei, Suju |
author_sort | Xu, Yu |
collection | PubMed |
description | The prognostic impact of baseline C-reactive protein (CRP) in patients with cancer receiving immune checkpoint inhibitors (ICIs) is unclear. The present meta-analysis aimed to review the prognostic value of baseline C-reactive protein (CRP) levels for patients with cancer receiving immunotherapy. Electronic databases, including PubMed, EMbase, Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure, WanFang, Chinese Literature Biomedical Database and Weipu Database, were used to identify cohort studies on the relationship between the baseline CRP levels and ICI survival outcomes from inception to November 2020. Literature screening, data extraction and quality evaluation of studies were independently performed by two reviewers. Subsequently, a meta-analysis was performed using STATA 14.0. A total of 13 cohort studies comprising 2,387 patients with cancer were included in the present meta-analysis. The results indicated that high baseline CRP levels (serum CRP measured within 2 weeks before ICI treatment) were associated with low overall survival (OS) and progression-free survival (PFS) rate among patients treated with ICIs. The subgroup analysis based on cancer type showed that high baseline CRP levels were associated with poor survival outcomes of multiple types of cancer, such as non-small cell lung cancer (6/13; 46.2%), melanoma (2/13; 15.4%), renal cell (3/13; 23.0%) and urothelial carcinoma (2/13; 15.4%). Similar results were observed in subgroup analysis based on the CRP cut-off value of 10 mg/l. In addition, a higher mortality risk was reported in patients with cancer and CRP ≥10 mg/l (hazard ratio, 2.76; 95% CI, 1.70-4.48; P<0.001). Compared with patients with low baseline CRP levels, increased baseline CRP levels were associated with low OS and PFS rate in patients with cancer receiving ICIs. Furthermore, CRP ≥10 mg/l indicated a worse prognosis. Therefore, baseline CRP levels may serve as a marker for the prognosis of patients with certain types of solid tumor treated with ICIs. Due to the limited quality and quantity of included studies, more prospective well-designed studies are required to verify the present findings. |
format | Online Article Text |
id | pubmed-10318603 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-103186032023-07-05 Association between baseline C‑reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta‑analysis Xu, Yu Ma, Ke Zhang, Fan Ma, Minting Hong, Lei Wang, Jing Li, Suping Sun, Panpan Wang, Junyan Wei, Suju Exp Ther Med Articles The prognostic impact of baseline C-reactive protein (CRP) in patients with cancer receiving immune checkpoint inhibitors (ICIs) is unclear. The present meta-analysis aimed to review the prognostic value of baseline C-reactive protein (CRP) levels for patients with cancer receiving immunotherapy. Electronic databases, including PubMed, EMbase, Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure, WanFang, Chinese Literature Biomedical Database and Weipu Database, were used to identify cohort studies on the relationship between the baseline CRP levels and ICI survival outcomes from inception to November 2020. Literature screening, data extraction and quality evaluation of studies were independently performed by two reviewers. Subsequently, a meta-analysis was performed using STATA 14.0. A total of 13 cohort studies comprising 2,387 patients with cancer were included in the present meta-analysis. The results indicated that high baseline CRP levels (serum CRP measured within 2 weeks before ICI treatment) were associated with low overall survival (OS) and progression-free survival (PFS) rate among patients treated with ICIs. The subgroup analysis based on cancer type showed that high baseline CRP levels were associated with poor survival outcomes of multiple types of cancer, such as non-small cell lung cancer (6/13; 46.2%), melanoma (2/13; 15.4%), renal cell (3/13; 23.0%) and urothelial carcinoma (2/13; 15.4%). Similar results were observed in subgroup analysis based on the CRP cut-off value of 10 mg/l. In addition, a higher mortality risk was reported in patients with cancer and CRP ≥10 mg/l (hazard ratio, 2.76; 95% CI, 1.70-4.48; P<0.001). Compared with patients with low baseline CRP levels, increased baseline CRP levels were associated with low OS and PFS rate in patients with cancer receiving ICIs. Furthermore, CRP ≥10 mg/l indicated a worse prognosis. Therefore, baseline CRP levels may serve as a marker for the prognosis of patients with certain types of solid tumor treated with ICIs. Due to the limited quality and quantity of included studies, more prospective well-designed studies are required to verify the present findings. D.A. Spandidos 2023-06-08 /pmc/articles/PMC10318603/ /pubmed/37408861 http://dx.doi.org/10.3892/etm.2023.12060 Text en Copyright: © 2023 Xu et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Xu, Yu Ma, Ke Zhang, Fan Ma, Minting Hong, Lei Wang, Jing Li, Suping Sun, Panpan Wang, Junyan Wei, Suju Association between baseline C‑reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta‑analysis |
title | Association between baseline C‑reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta‑analysis |
title_full | Association between baseline C‑reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta‑analysis |
title_fullStr | Association between baseline C‑reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta‑analysis |
title_full_unstemmed | Association between baseline C‑reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta‑analysis |
title_short | Association between baseline C‑reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta‑analysis |
title_sort | association between baseline c‑reactive protein level and survival outcomes for cancer patients treated with immunotherapy: a meta‑analysis |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318603/ https://www.ncbi.nlm.nih.gov/pubmed/37408861 http://dx.doi.org/10.3892/etm.2023.12060 |
work_keys_str_mv | AT xuyu associationbetweenbaselinecreactiveproteinlevelandsurvivaloutcomesforcancerpatientstreatedwithimmunotherapyametaanalysis AT make associationbetweenbaselinecreactiveproteinlevelandsurvivaloutcomesforcancerpatientstreatedwithimmunotherapyametaanalysis AT zhangfan associationbetweenbaselinecreactiveproteinlevelandsurvivaloutcomesforcancerpatientstreatedwithimmunotherapyametaanalysis AT maminting associationbetweenbaselinecreactiveproteinlevelandsurvivaloutcomesforcancerpatientstreatedwithimmunotherapyametaanalysis AT honglei associationbetweenbaselinecreactiveproteinlevelandsurvivaloutcomesforcancerpatientstreatedwithimmunotherapyametaanalysis AT wangjing associationbetweenbaselinecreactiveproteinlevelandsurvivaloutcomesforcancerpatientstreatedwithimmunotherapyametaanalysis AT lisuping associationbetweenbaselinecreactiveproteinlevelandsurvivaloutcomesforcancerpatientstreatedwithimmunotherapyametaanalysis AT sunpanpan associationbetweenbaselinecreactiveproteinlevelandsurvivaloutcomesforcancerpatientstreatedwithimmunotherapyametaanalysis AT wangjunyan associationbetweenbaselinecreactiveproteinlevelandsurvivaloutcomesforcancerpatientstreatedwithimmunotherapyametaanalysis AT weisuju associationbetweenbaselinecreactiveproteinlevelandsurvivaloutcomesforcancerpatientstreatedwithimmunotherapyametaanalysis |